Phase II ERCC 1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

Histologically confirmed, surgically resected Stage IA (with longest tumor diameter </= 2 cm) or Stage IB NSCLC. Must have tissue from resection available and agree to have tx assignment based on gene expression analysis on tissue. Must submit specimen within 7 days after reg. Must have all dz completely resected (R0). Surgical criteria in Section 5.3 must be met. PET within 84 days prior to registration. No prior systemic chemo or biologics for lung cancer. No prior thoracic RT. Zubrod 0-1. Within 28 days prior to reg: ANC >/= 1,500/mcl; platelets >/= 100,000/mcl; hemoglobin >\= 10 mg/dl; bilirubin </= 1.5xIULN; SGOT or SGPT </= 1.5xIULN; serum creatinine </= 1.5 x IULN OR creatinine clearance >/= 60 mL/min. Not planning to receive other treatment while on protocol tx. No other prior malignancy except those specified in Section 5.12. Must be willing to provide smoking hx. Must be offered participation in banking of specimens. Must not be pregnant or nursing.